ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1026

Impact Of Basing Rheumatoid Arthritis Disease Activity Measurement and Treatment Recommendations On Patient Instead Of Physician Joint Assessments

Yomei Shaw1, Daisy Bang2, Heather Eng3, Stephen R. Wisniewski4, Mark S. Roberts1 and Marc C. Levesque5, 1Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 2Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, 3Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 4Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 5Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Disease Activity, patient-reported outcome measures, rheumatoid arthritis (RA) and therapeutic targeting

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Current guidelines recommend treatment for rheumatoid arthritis (RA) be informed by a measure of disease activity such as the Disease Activity Score-28 (DAS28-CRP), which includes physician assessments of tenderness and swelling in joints.  We explored the impact of basing disease activity measurement and treatment recommendations for RA patients on patient joint assessments rather than physician assessments.

Methods: 364 RA subjects enrolled in the Rheumatoid Arthritis Comparative Effectiveness Research (RACER) registry and their physicians performed independent and blinded exams of 28 joints for tenderness and swelling during routine clinic visits.  Subjects assessed their own joints assisted by a web-based tool that provided illustrations and instructions.  We measured discrepancies in the DAS28-CRP, disease activity categories and treatment recommendations (following American College of Rheumatology (ACR) guidelines for therapy adjustment) when based on patient vs. physician assessments.  Treatment recommendations were compared with actual treatment decisions for 342 subjects.

Results: Mean DAS28-CRP scores based on patient assessments were higher than when based on physician assessments (mean ±SD, 3.49 ±1.50 vs. 3.02 ±1.25; p<0.0001).  In 56% of 364 cases, the patient and physician-based DAS28-CRP led to categorization in the same disease severity level; in 44% of cases the patient and physician-based scores led to discrepant categorizations.  In 84% of cases the physician and patient-based scores would yield the same recommendation regarding therapy adjustment, but in 16% of cases they would yield different recommendations.  When evaluating actual decisions against treatment recommendations based on ACR guidelines (n=342), only 8.77% of patients actually adjusted therapy, compared to 33.33% and 39.18% recommended to adjust therapy according to physician and patient DAS28-CRP, respectively (Table 1).  Actual rates of therapy adjustment were low among those subjects recommended to adjust therapy (16.7% when assessed by physician DAS28-CRP and 14.9% when assessed by patient DAS28-CRP (Table 1)).

Conclusion: Although discrepancies in disease severity categorization occurred frequently (44% of the time), discrepancies in RA treatment recommendations arose less frequently (16% of the time) as a result of differences in patient and physician joint exams.  Regardless of whether treatment recommendations were based on patient or physician joint exams, actual treatment decisions often appeared to be inconsistent with disease severity, primarily because therapy was often not adjusted despite > 3 months of moderate to high disease activity.  Further research will explore disease and health-related outcomes associated with miscategorizing disease severity and under-treating RA patients.


Disclosure:

Y. Shaw,

Genentech and Biogen IDEC Inc.,

2;

D. Bang,
None;

H. Eng,

Genentech and Biogen IDEC Inc.,

2;

S. R. Wisniewski,

Genentech and Biogen IDEC Inc.,

2;

M. S. Roberts,
None;

M. C. Levesque,

Genentech and Biogen IDEC Inc.,

2,

UCB,

5,

AbbVie,

9,

Crescendo,

5,

Baxter Healthcare,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-basing-rheumatoid-arthritis-disease-activity-measurement-and-treatment-recommendations-on-patient-instead-of-physician-joint-assessments/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology